PortfoliosLab logo
AMRX vs. COHR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AMRX and COHR is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

AMRX vs. COHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amneal Pharmaceuticals, Inc. (AMRX) and Coherent, Inc. (COHR). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%1,000.00%1,200.00%December2025FebruaryMarchAprilMay
52.00%
717.28%
AMRX
COHR

Key characteristics

Sharpe Ratio

AMRX:

0.19

COHR:

0.32

Sortino Ratio

AMRX:

0.56

COHR:

0.96

Omega Ratio

AMRX:

1.06

COHR:

1.13

Calmar Ratio

AMRX:

0.08

COHR:

0.42

Martin Ratio

AMRX:

0.70

COHR:

1.08

Ulcer Index

AMRX:

9.77%

COHR:

21.58%

Daily Std Dev

AMRX:

35.97%

COHR:

72.98%

Max Drawdown

AMRX:

-97.52%

COHR:

-80.89%

Current Drawdown

AMRX:

-85.93%

COHR:

-37.85%

Fundamentals

Market Cap

AMRX:

$3.51B

COHR:

$10.99B

EPS

AMRX:

-$0.04

COHR:

-$0.40

PS Ratio

AMRX:

1.24

COHR:

2.07

PB Ratio

AMRX:

86.10

COHR:

2.13

Total Revenue (TTM)

AMRX:

$2.83B

COHR:

$4.10B

Gross Profit (TTM)

AMRX:

$1.04B

COHR:

$1.40B

EBITDA (TTM)

AMRX:

$511.54M

COHR:

$742.80M

Returns By Period

In the year-to-date period, AMRX achieves a -8.84% return, which is significantly higher than COHR's -26.51% return. Over the past 10 years, AMRX has underperformed COHR with an annualized return of -16.78%, while COHR has yielded a comparatively higher 14.49% annualized return.


AMRX

YTD

-8.84%

1M

0.14%

6M

-15.06%

1Y

10.91%

5Y*

15.32%

10Y*

-16.78%

COHR

YTD

-26.51%

1M

31.78%

6M

-29.98%

1Y

25.90%

5Y*

14.27%

10Y*

14.49%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AMRX vs. COHR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMRX
The Risk-Adjusted Performance Rank of AMRX is 5656
Overall Rank
The Sharpe Ratio Rank of AMRX is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of AMRX is 5454
Sortino Ratio Rank
The Omega Ratio Rank of AMRX is 5050
Omega Ratio Rank
The Calmar Ratio Rank of AMRX is 5656
Calmar Ratio Rank
The Martin Ratio Rank of AMRX is 6161
Martin Ratio Rank

COHR
The Risk-Adjusted Performance Rank of COHR is 6565
Overall Rank
The Sharpe Ratio Rank of COHR is 6464
Sharpe Ratio Rank
The Sortino Ratio Rank of COHR is 6464
Sortino Ratio Rank
The Omega Ratio Rank of COHR is 6464
Omega Ratio Rank
The Calmar Ratio Rank of COHR is 7070
Calmar Ratio Rank
The Martin Ratio Rank of COHR is 6565
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AMRX vs. COHR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Coherent, Inc. (COHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current AMRX Sharpe Ratio is 0.19, which is lower than the COHR Sharpe Ratio of 0.32. The chart below compares the historical Sharpe Ratios of AMRX and COHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00December2025FebruaryMarchAprilMay
0.31
0.36
AMRX
COHR

Dividends

AMRX vs. COHR - Dividend Comparison

Neither AMRX nor COHR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AMRX vs. COHR - Drawdown Comparison

The maximum AMRX drawdown since its inception was -97.52%, which is greater than COHR's maximum drawdown of -80.89%. Use the drawdown chart below to compare losses from any high point for AMRX and COHR. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-85.93%
-37.85%
AMRX
COHR

Volatility

AMRX vs. COHR - Volatility Comparison

The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 14.26%, while Coherent, Inc. (COHR) has a volatility of 28.98%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than COHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%December2025FebruaryMarchAprilMay
14.26%
28.98%
AMRX
COHR

Financials

AMRX vs. COHR - Financials Comparison

This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Coherent, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


400.00M600.00M800.00M1.00B1.20B1.40B20212022202320242025
695.42M
1.44B
(AMRX) Total Revenue
(COHR) Total Revenue
Values in USD except per share items

AMRX vs. COHR - Profitability Comparison

The chart below illustrates the profitability comparison between Amneal Pharmaceuticals, Inc. and Coherent, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

25.0%30.0%35.0%40.0%20212022202320242025
36.8%
35.5%
(AMRX) Gross Margin
(COHR) Gross Margin
AMRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a gross profit of 255.89M and revenue of 695.42M. Therefore, the gross margin over that period was 36.8%.

COHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Coherent, Inc. reported a gross profit of 509.00M and revenue of 1.44B. Therefore, the gross margin over that period was 35.5%.

AMRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported an operating income of 100.35M and revenue of 695.42M, resulting in an operating margin of 14.4%.

COHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Coherent, Inc. reported an operating income of 144.00M and revenue of 1.44B, resulting in an operating margin of 10.0%.

AMRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a net income of 24.62M and revenue of 695.42M, resulting in a net margin of 3.5%.

COHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Coherent, Inc. reported a net income of 103.39M and revenue of 1.44B, resulting in a net margin of 7.2%.